Combination gene therapy targeting on interleukin-1β and RANKL for wear debris-induced aseptic loosening

No Thumbnail Available
Wang, H.
Jia, Tanghong
Zacharias, Nora M.
Gong, Weiming
Du, Hongxia
Wooley, Paul H.
Yang, Shang-You
Issue Date
Research Projects
Organizational Units
Journal Issue
H Wang, T-H Jia, N Zacharias, W Gong, H-X Du, P H Wooley, S-Y Yang; Combination gene therapy targeting on interleukin-1[beta] and RANKL for wear debris-induced aseptic loosening; Gene Ther Feb.2013, V.20, No.2; P128-135

This study investigated the efficacy of a combination gene therapy to repress interleukin-1 (IL-1) and receptor activator of nuclear factor NF-kappa B ligand (RANKL) for the treatment of particulate debris-induced aseptic loosening, and tried to explore the molecular mechanism of the exogenous gene modifications on osteoclastogenesis. RAW cells activated by titanium particles were transduced with DFG-IL-1Ra (retroviral vector encoding IL-1 receptor antagonist) and AAV-OPG (adeno-associated viral vectors—osteoprotegerin) individually or in combination for 4 weeks. Pro-inflammatory cytokines in culture media were determined by enzyme-linked immunosorbent assay, and gene expressions of RANK, IL-1β, c-Fos, TRAF6, JNK1 and CPK were examined using real-time PCR. An established knee-implant-failure mouse model was employed to evaluate the efficacy of the in vivo double-gene therapy. The surgical implantation of a titanium alloy pin into the proximal tibia was followed by monthly challenge with titanium debris. Peri-implant gene transfers of IL-1Ra and OPG (respectively or in combination) were given 3 weeks after surgery. The combination of OPG and IL-1Ra gene transfer exhibited strong synergetic effects in blockage of inflammation and osteoclastogenesis at 8 weeks after gene modification. The combination therapy reversed peri-implant bone resorption and restored implant stability when compared with either single gene transduction. Real-time PCR data indicated that the action of IL-1Ra gene therapy may be mediated via the JNK1 pathway, while the reduction of osteoclastogenesis by OPG gene modification may be regulated by c-Fos expression. In addition, both gene modifications resulted in significant diminishment of TRAF6 expression.

Table of Contents
Click on the DOI link to access this article (may not be free)
Macmillan Publishers Limited
Book Title
Gene Therapy;
;V.20, No.2
PubMed ID
1476-5462 (Electronic)
0969-7128 (Linking)